Harborside


Core One Labs Inc.

CNSX: COOL


Canadian symbol: COOL.CN
US symbol: CLABF

Currency in CAD

Valuation Measures4

Market Cap (intraday) 14.06M
Enterprise Value 11.89M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)3.29
Enterprise Value/Revenue 17.05
Enterprise Value/EBITDA -0.21

Trading Information

Stock Price History

Beta (5Y Monthly) 2.56
52-Week Change 3-72.04%
S&P500 52-Week Change 322.93%
52 Week High 311.8400
52 Week Low 30.8500
50-Day Moving Average 31.4360
200-Day Moving Average 34.8120

Share Statistics

Avg Vol (3 month) 362.77k
Avg Vol (10 day) 339.19k
Shares Outstanding 514.34M
Implied Shares Outstanding 6N/A
Float 815.36M
% Held by Insiders 14.24%
% Held by Institutions 12.53%
Shares Short (Nov. 14, 2021) 417.15k
Short Ratio (Nov. 14, 2021) 40.53
Short % of Float (Nov. 14, 2021) 4N/A
Short % of Shares Outstanding (Nov. 14, 2021) 40.12%
Shares Short (prior month Oct. 14, 2021) 494.53k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:8
Last Split Date 3Jul. 14, 2021

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2020
Most Recent Quarter (mrq)Sep. 29, 2021

Profitability

Profit Margin 0.00%
Operating Margin (ttm)1,466.55%

Management Effectiveness

Return on Assets (ttm)-57.08%
Return on Equity (ttm)-771.93%

Income Statement

Revenue (ttm)-997.2k
Revenue Per Share (ttm)-0.08
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -14.14M
Net Income Avi to Common (ttm)-59.28M
Diluted EPS (ttm)-5.0900
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)697.04k
Total Cash Per Share (mrq)0.05
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.90
Book Value Per Share (mrq)0.28

Cash Flow Statement

Operating Cash Flow (ttm)-5.28M
Levered Free Cash Flow (ttm)-5.66M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
COOL.CN
Core One Labs
4 months ago
COOL.CN
Core One Labs
4 months ago
COOL.CN
Core One Labs
11 months ago
COOL.CN
Core One Labs
1 year ago
COOL.CN
Core One Labs
1 year ago
COOL.CN
Core One Labs
1 year ago
COOL.CN
Core One Labs
1 year ago
COOL.CN
Core One Labs
1 year ago
COOL.CN
Core One Labs
1 year ago
COOL.CN
Core One Labs
1 year ago
COOL.CN
Core One Labs
1 year ago
COOL.CN
Core One Labs
1 year ago
COOL.CN
Core One Labs
1 year ago
COOL.CN
Core One Labs
1 year ago
COOL.CN
Core One Labs
1 year ago
COOL.CN
Core One Labs
1 year ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago
COOL.CN
Core One Labs
2 years ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
4.24%% of Shares Held by All Insider
2.53%% of Shares Held by Institutions
2.64%% of Float Held by Institutions
3Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Core One Labs Inc.


Core One Labs Applauds the City of Seattle in Their Efforts to Decriminalize Psylocibin and Other Natural Occuring Entheogenic Drugs

Core One Labs Applauds the City of Seattle in Their Efforts to Decriminalize Psylocibin and Other Natural Occuring Entheogenic Drugs

VANCOUVER, British Columbia, Oct. 16, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (FWB: LD6, WKN: A3CSSU) (the “Company”) a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy, congratulates Seattle’s city c... Read More...
Core One Labs' Clinics Submit Application to Treat Patient With Psilocybin Psychedelic-Assisted Therapy

Core One Labs’ Clinics Submit Application to Treat Patient With Psilocybin Psychedelic-Assisted Therapy

VANCOUVER, British Columbia, Aug. 13, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy is pleased to announce th... Read More...
Core One Labs to Move Its Psychedelic Formulations for the Treatment of Stroke and Depression Toward Clinical Development

Core One Labs to Move Its Psychedelic Formulations for the Treatment of Stroke and Depression Toward Clinical Development

VANCOUVER, British Columbia, Aug. 07, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that the scientific team of its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has initiated the next step in their clinical development designs for the use of... Read More...
Core One Labs' Virtual Town Hall Reveals Company is Nearing Production of Biosynthesized Psilocybin: Breakthrough In the Psychedelic Space Expected Upon Successful Completion

Core One Labs’ Virtual Town Hall Reveals Company is Nearing Production of Biosynthesized Psilocybin: Breakthrough In the Psychedelic Space Expected Upon Successful Completion

VANCOUVER, British Columbia, Aug. 04, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is a research and development company focused on bringing psychedelic medicines to market through the development and production of API grade psychedelic compounds, the advancement of psyc... Read More...
Core One's Dr. Robert E.W. Hancock to Host Virtual Townhall Webcast and Present on Proprietary Biosynthesized Psilocybin Wednesday, August 4, 2021

Core One’s Dr. Robert E.W. Hancock to Host Virtual Townhall Webcast and Present on Proprietary Biosynthesized Psilocybin Wednesday, August 4, 2021

VANCOUVER, British Columbia, July 30, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that Dr. Robert E.W. Hancock, the Company’s Chairman, and CEO of its wholly owned subsidiary Vocan Biotechnologies Inc. will be presenting at the Company’s Virtual T... Read More...
Core One Labs' Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment

Core One Labs’ Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment

VANCOUVER, British Columbia, July 21, 2021 -- Core One Labs Inc. (CSE: COOL) (OTC: CLABD) (Frankfurt: LD6, WKN:A3CSSU) (the “Company”) is excited to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has protected its breakthrough ketamine psychedelic drug formulation for the treatment of Depression and is set to begin... Read More...
Core One Labs to Present on its Proprietary Biosynthetic Psilocybin Technology at Investor Town Hall Event on August 4, 2021

Core One Labs to Present on its Proprietary Biosynthetic Psilocybin Technology at Investor Town Hall Event on August 4, 2021

VANCOUVER, British Columbia, July 17, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that Dr. Robert E.W. Hancock, the Company’s Chairman, and CEO of its wholly owned subsidiary Vocan Biotechnologies Inc. (“Vocan”) will be presenting at a Company hos... Read More...
Core One Labs Announces Details of Consolidation to Meet Nasdaq Listing Requirements

Core One Labs Announces Details of Consolidation to Meet Nasdaq Listing Requirements

VANCOUVER, British Columbia, July 16, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that it is pursuing a listing on the Capital Market tier of The Nasdaq Stock Market LLC (“Nasdaq”) to enhance the Company’s investor profile and increase value for i... Read More...
Core One Labs Retains Canada's Highest-Ranked IP Law Firm to Assist With Patent Filings

Core One Labs Retains Canada’s Highest-Ranked IP Law Firm to Assist With Patent Filings

VANCOUVER, British Columbia, June 18, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce it has retained Smart & Biggar LLP (“Smart and Biggar”) to handle all IP filings for Akome Biotech Ltd. (“Akome”) and Vocan Biotechnologies Inc. (“Vocan”). Smart & Biggar... Read More...
Core One Labs Plans Share Consolidation in Preparation of Listing its Common Shares on Nasdaq

Core One Labs Plans Share Consolidation in Preparation of Listing its Common Shares on Nasdaq

VANCOUVER, British Columbia, June 16, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) advises that in preparation of a potential listing of its common shares on the Capital Market tier of The Nasdaq Stock Market LLC (“Nasdaq” or the “Exchange”), the Company is planning a s... Read More...
Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer's Disease

Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease

VANCOUVER, British Columbia, May 06, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has commenced the development of its next-generation patent pending psychedelic drug formulation for th... Read More...
Core One Labs to Explore Joint Venture with Lobe Sciences for the Clinical Development of Biosynthetic Psilocybin

Core One Labs to Explore Joint Venture with Lobe Sciences for the Clinical Development of Biosynthetic Psilocybin

VANCOUVER, British Columbia, April 28, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce it has entered into a letter of intent, dated April 27, 2021, with Lobe Sciences Ltd. (“Lobe”) pursuant to which the Company will explore the formation of a joint ... Read More...
Repeat: Core One Labs Vocan Biotechnologies Enters into Collaborative Research Agreement with UBC

Repeat: Core One Labs Vocan Biotechnologies Enters into Collaborative Research Agreement with UBC

VANCOUVER, British Columbia, April 26, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce its wholly owned subsidiary Vocan, has entered into a Collaborative Research Agreement with the University of British Columbia (“UBC” or the “University”). Research will be cond... Read More...
Core One Labs Vocan Biotechnologies Enters into Collaborative Research Agreement with UBC

Core One Labs Vocan Biotechnologies Enters into Collaborative Research Agreement with UBC

VANCOUVER, British Columbia, April 24, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce its wholly owned subsidiary Vocan, has entered into a Collaborative Research Agreement with the University of British Columbia (“UBC” or the “University”). Research will be cond... Read More...
Core One Labs' Vocan Initiates Engineering and Design of a Proprietary Production System for Manufacturing of API-Grade DMT

Core One Labs’ Vocan Initiates Engineering and Design of a Proprietary Production System for Manufacturing of API-Grade DMT

VANCOUVER, British Columbia, April 21, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or ”Core One”) a life sciences research and technology company focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy is pleased to an... Read More...
Repeat: Core One Labs Files Application to List its Common Shares on NASDAQ

Repeat: Core One Labs Files Application to List its Common Shares on NASDAQ

VANCOUVER, British Columbia, March 22, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (“Core One” or the “Company”) is pleased to announce that it has filed an application to list its common shares on the Capital Market tier of The NASDAQ Stock Market LLC (“Nasdaq”). Nasdaq is ranked as the second-lar... Read More...
Core One Labs Files Application to List its Common Shares on NASDAQ

Core One Labs Files Application to List its Common Shares on NASDAQ

VANCOUVER, British Columbia, March 20, 2021 -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (“Core One” or the “Company”) is pleased to announce that it has filed an application to list its common shares on the Capital Market tier of The NASDAQ Stock Market LLC (“Nasdaq”). Nasdaq is ranked as the second-lar... Read More...
Core One Labs Announces Vocan Assembles Equipment to Produce Biosynthesized Psilocybin

Core One Labs Announces Vocan Assembles Equipment to Produce Biosynthesized Psilocybin

VANCOUVER, BC / ACCESSWIRE / January 23, 2021 /Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62)(WKN:A2P8K3) (the "Company") is pleased to announce its wholly-owned subsidiary Vocan Biotechnologies Inc. ("Vocan") has assembled the necessary equipment, which will allow the laboratory to commence the process of recombinant produ... Read More...
Leading Microbiologist, Dr. Robert E.W. Hancock Appointed as Executive Chairman of Core One Labs

Leading Microbiologist, Dr. Robert E.W. Hancock Appointed as Executive Chairman of Core One Labs

VANCOUVER, BC / ACCESSWIRE / January 7, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the "Company" or "Core One") is pleased to announce the appointment of Dr. Robert E.W. Hancock as Executive Chairman of the Company, effective January 6, 2021.Dr. Hancock is an internationally renowned academic in Mi... Read More...
Core One Labs Signs Definitive Agreement for Acquisition of Biosynthetic Psilocybin Research Firm Vocan Biotechnologies Inc.

Core One Labs Signs Definitive Agreement for Acquisition of Biosynthetic Psilocybin Research Firm Vocan Biotechnologies Inc.

VANCOUVER, BC / ACCESSWIRE / December 24, 2020 / Core One Labs Inc. (CSE:COOL), (OTC:CLABF), (Frankfurt:LD62), (WKN:A14XHT) (the "Company") is pleased to announce that, further to its press release of October 7, 2020, it has entered into a definitive share purchase agreement (the "Purchase Agreement"), dated December 23, 2020, for the acq... Read More...
Core One Labs Provides Update on Financial Statements and Management Cease Trade Order

Core One Labs Provides Update on Financial Statements and Management Cease Trade Order

VANCOUVER, BC / ACCESSWIRE / July 15, 2020 / Core One Labs Inc. (COOL.CN)(CLABD)(LD62.F)(WKN:A2P8K3) (the "Company"). The Company wishes to advise its valued shareholders that the new management team ("Management") is currently working with its auditor and accountants around the clock to finalize its audited financial statements and the r... Read More...
Core One Labs Requests Management Cease Trade Order for Additional Time to Complete Annual Financial Statements and Related Filings

Core One Labs Requests Management Cease Trade Order for Additional Time to Complete Annual Financial Statements and Related Filings

Vancouver, British Columbia--(Newsfile Corp. - June 9, 2020) -  Core One Labs Inc. (CSE: COOL) (OTCQX: CLABF) (FSE: LD6) (WKN: A14XHT) ("COOL" or the "Company") announced today that it anticipates additional delays in filing its financial statements for the year ended December 31, 2019 and the related management's discussion and analysis ... Read More...
Core One Labs Announces Private Placement Financing and Non-Binding Letter of Intent to Acquire Medical Clinics

Core One Labs Announces Private Placement Financing and Non-Binding Letter of Intent to Acquire Medical Clinics

Vancouver, British Columbia--(Newsfile Corp. - June 5, 2020) - Core One Labs Inc. (CSE: COOL) (OTCQX: CLABF) (FSE: LD61) (WKN: A14XHT) (the "Company") is pleased to announce that it has entered into a non-binding letter of intent (the "Letter of Intent"), dated June 4, 2020, with Rejuva Alternative Medicine Research Centre Inc. ("Rejuva")... Read More...
Core One Labs Inc. Announces Cancellation of Loan with Viva Capital Ventures, LLC and Grant of Incentive Stock Options

Core One Labs Inc. Announces Cancellation of Loan with Viva Capital Ventures, LLC and Grant of Incentive Stock Options

Vancouver, British Columbia--(Newsfile Corp. - June 1, 2020) -  Core One Labs Inc. (CSE: COOL) (OTCQX: CLABF) (FSE: LD61) (WKN: A14XHT) ("COOL") announced that it has cancelled the loan transaction with Viva Capital Ventures, LLC ("Viva"). As previously announced, the Company's wholly owned subsidiary, LDS Development Corporation ("LDS De... Read More...
Core One Labs' Subsidiary Signs Loan for USD$900,000; Also Announces Extension of Filing Deadline for Annual and Interim Financial Statements and MD&A, Settlement of Debts for Shares and Resignation of CFO

Core One Labs’ Subsidiary Signs Loan for USD$900,000; Also Announces Extension of Filing Deadline for Annual and Interim Financial Statements and MD&A, Settlement of Debts for Shares and Resignation of CFO

Vancouver, British Columbia--(Newsfile Corp. - April 29, 2020) - Core One Labs Inc. (CSE: COOL) (OTCQX: CLABF) (FSE: LD6) (WKN: A14XHT) ("COOL") announces that its wholly owned subsidiary, LDS Development Corporation, has entered into an agreement with Viva Capital Ventures LLC ("Viva") for a secured loan for USD$900,000 (the "Loan"). The... Read More...
Core One Labs' Subsidiary, Core Isogenics Inc., Completes 7th and 8th Harvests of Top Grade Flower at the Adelanto Indoor Grow

Core One Labs’ Subsidiary, Core Isogenics Inc., Completes 7th and 8th Harvests of Top Grade Flower at the Adelanto Indoor Grow

Vancouver, British Columbia--(Newsfile Corp. - February 19, 2020) - Core One Labs Inc. (CSE: COOL) (OTCQX: CLABF) (FSE: LD6) (WKN: A14XHT) ("COOL") announces that its wholly-owned subsidiary, Core Isogenics Inc., has completed its seventh and eighth consecutive harvests at the Adelanto facility.The Core Isogenics' nursery and cultivation ... Read More...
Core One Labs' Subsidiary, Core Isogenics Inc., in Association with Reiziger Pty. Ltd. Begins to Show Strong Results

Core One Labs’ Subsidiary, Core Isogenics Inc., in Association with Reiziger Pty. Ltd. Begins to Show Strong Results

Vancouver, British Columbia--(Newsfile Corp. - February 18, 2020) - Core One Labs Inc. (CSE: COOL) (OTCQX: CLABF) (FSE: LD61) (WKN: A14XHT) ("COOL") announces that its wholly-owned subsidiary, Core Isogenics Inc., has begun a highly complex nutritional regimen to accelerate the growth of cannabis plants and increase flower yield and quali... Read More...
Core One Labs Inc. Subsidiary, CSPA Group, Inc., Continues to Expand Extraction Capabilities with White Label and Wholesale Products

Core One Labs Inc. Subsidiary, CSPA Group, Inc., Continues to Expand Extraction Capabilities with White Label and Wholesale Products

Vancouver, British Columbia--(Newsfile Corp. - January 28, 2020) - Core One Labs Inc. (CSE: COOL) (OTCQX: CLABF) (FSE: LD6) (WKN: A14XHT) ("COOL") announces that its wholly-owned subsidiary, CSPA Group, Inc. ("CSPA"), continues to expand its extraction capability using Color Remediation Technology ("CRT").CSPA has expanded production to a... Read More...
Core One Labs' Rêveur Brand is Gaining Consumer Traction with its High Yield In-House Product

Core One Labs’ Rêveur Brand is Gaining Consumer Traction with its High Yield In-House Product

Vancouver, British Columbia--(Newsfile Corp. - January 23, 2020) - Core One Labs Inc. (CSE: COOL) (OTCQX: CLABF) (FSE: LD6) (WKN: A14XHT) ("COOL") is pleased to see an increase in demand for Rêveur branded product being produced in its Adelanto facility.Rêveur live Resin and Indoor Flower is currently being sold through the Company's dist... Read More...
Coming Soon.
SymbolExchangePriceChangeAs of
COOL.CD
Canadian Securities Exchange - CSE Listed
Canadian Securities Exchange - CSE Listed0.85CAD-5.56%
LD6.F
Frankfurt Stock Exchange
Frankfurt Stock Exchange0.58EUR-4.61%
COOL.CCP
Canadian Composite Quote/Trade
Canadian Composite Quote/Trade0.85CAD-5.56%
CLABF.PK
US 'Other OTC' and Grey Market
US 'Other OTC' and Grey Market0.66USD-7.69%
LD6.SG
Stuttgart Stock Exchange
Stuttgart Stock Exchange0.58EUR-3.97%
LD6.MU
Munich Stock Exchange
Munich Stock Exchange0.61EUR+0.83%
CLABF.PQ
OTC MARKETS GROUP L1 AND L2
OTC MARKETS GROUP L1 AND L20.69USD-1.59%

Delayed data (1h)
NameAgePositionAppointed
Robert E. W. Hancock
Executive Chairman of the Board
--Executive Chairman of the Board2021
Casey Fenwick
President
--President2019
Joel Shacker
Chief Executive Officer, Director
--Chief Executive Officer, Director2020
Geoff Balderson
Chief Financial Officer, Corporate Secretary, Director
40Chief Financial Officer, Corporate Secretary, Director2021
John Sanderson
Director
67Director2021
Ryan Hoggan
Independent Director
--Independent Director2020
Patrick Morris
Independent Director
52Independent Director2020


Share this page